It was great to speak at CGTI EU in Berlin about CREATe Therapeutics' work on drug-controlled CNS gene therapy—a platform we’re developing to address a range of neurological disorders, with drug-resistant focal epilepsy as our lead indication

.It was energizing to share our approach and exchange ideas with so many colleagues pushing the boundaries of what’s possible in CNS therapeutics. The discussions and feedback were invaluable, and I’m grateful to the CGTI community for the engagement.

Excited to continue advancing this work with the team at CREATe Therapeutics.